MBRX: Moleculin Price Target Chart

The production cycle of Moleculin Biotech, Inc. (MBRX) is based on a distributed network of external contractors in Europe and the US, which eliminates disruptions in drug manufacturing. This chart shows the market price at 238.96, illustrating the asset's price action. However, geopolitical tensions and sanctions are hindering global tests and component deliveries. A specific bias toward a single technology is offset by the simultaneous study of lung and brain tumor therapies.

MBRX: Moleculin Consensus Target 07/04/2022 - 11/11/2026

Metric breakdowns and analytics for Moleculin Biotech, Inc. (MBRX)

- market price and analyst price targets:

Stock Quotes moleculin.com|MBRX - Analyst Consensus Forecast

- market capitalization information:

Market Value Moleculin|MBRX - Total Company Value

- issuer book value statistics:

Accounting Value of a Share Moleculin Biotech|MBRX - Company Net Assets|Capitalization to Book Value Ratio moleculin.com|MBRX - Aggregate Company Assets

- issuer credit burden and liquidity indicators:

- earnings and valuation multiples information:

MBRX - Company Net Income|Expected Net Profit Moleculin Biotech, Inc.|MBRX - P/E Multiple|Forward Price to Earnings Multiple moleculin.com|MBRX - Price/Earnings to Growth Multiple|Company Value to EBITDA Moleculin|MBRX - Operating profit before deduction of amortization|Earnings per share for the trailing year Moleculin Biotech|MBRX - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months moleculin.com|MBRX - Earnings per share growth in current year|Net earnings per share growth forecast for next year Moleculin Biotech, Inc.

General company analysis:MBRX (Moleculin Biotech Inc)

Mass-produced product of Moleculin Biotech Inc

The consensus forecast reflects the average fair value of shares calculated by analysts based on discounted cash flows and a fundamental business revaluation. By analyzing the trend of target valuations from the investment community on GURU.Markets, an investor can compare the market price with the potential of Moleculin Biotech, Inc. (MBRX), which is supported by high confidence among oncologists in its unique drug platform for crossing the blood-brain barrier.

Competitors of Moleculin Biotech, Inc.